Comparative Pharmacology
Head-to-head clinical analysis: CLINDETS versus POLYSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDETS versus POLYSPORIN.
CLINDETS vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation. It also acts as a competitive inhibitor of bacterial ribosomal RNA methyltransferases.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Clindamycin: 150-450 mg orally every 6 hours; 600-900 mg IV every 8 hours. Max: 1.8 g/day for severe infections.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
Terminal elimination half-life is 2.4-3 hours in adults; prolonged to 4-6 hours in severe hepatic impairment.
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Approximately 10% of the dose is excreted unchanged in urine; the remainder is hepatically metabolized and eliminated via bile (fecal: ~40%) and urine as inactive metabolites.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic
Topical Antibiotic